Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mechanism of efficacy of trabectedin against myxoid liposarcoma entails detachment of the FUS-DDIT3 transcription factor from its DNA binding sites.
Craparotta I, Mannarino L, Zadro R, Ballabio S, Marchini S, Pavesi G, Russo M, Renne SL, Meroni M, Ponzo M, Bello E, Sanfilippo R, Casali PG, D'Incalci M, Frapolli R. Craparotta I, et al. Among authors: ballabio s. J Exp Clin Cancer Res. 2024 Nov 26;43(1):309. doi: 10.1186/s13046-024-03228-z. J Exp Clin Cancer Res. 2024. PMID: 39587691 Free PMC article.
Corrigendum to "Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma" [Genomics Volume 113, Issue 5, September 2021, Pages 3439-3448].
Mannarino L, Craparotta I, Ballabio S, Frapolli R, Meroni M, Bello E, Panini N, Callari M, Sanfilippo R, Casali PG, Barisella M, Fabbroni C, Marchini S, D'Incalci M. Mannarino L, et al. Among authors: ballabio s. Genomics. 2022 Jan;114(1):473. doi: 10.1016/j.ygeno.2021.09.005. Epub 2021 Sep 10. Genomics. 2022. PMID: 34535324 Free article. No abstract available.
Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma.
Mannarino L, Craparotta I, Ballabio S, Frapolli R, Meroni M, Bello E, Panini N, Callari M, Sanfilippo R, Casali PG, Barisella M, Fabbroni C, Marchini S, D'Incalci M. Mannarino L, et al. Among authors: ballabio s. Genomics. 2021 Sep;113(5):3439-3448. doi: 10.1016/j.ygeno.2021.07.028. Epub 2021 Jul 30. Genomics. 2021. PMID: 34339817 Free article.
Correction: Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas.
Frapolli R, Bello E, Ponzo M, Craparotta I, Mannarino L, Ballabio S, Marchini S, Carrassa L, Ubezio P, Porcu L, Brich S, Sanfilippo R, Casali PG, Gronchi A, Pilotti S, D'Incalci M. Frapolli R, et al. Among authors: ballabio s. Clin Cancer Res. 2020 Mar 1;26(5):1199. doi: 10.1158/1078-0432.CCR-20-0172. Clin Cancer Res. 2020. PMID: 32122930 No abstract available.
Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.
Benvenuto G, Todeschini P, Paracchini L, Calura E, Fruscio R, Romani C, Beltrame L, Martini P, Ravaggi A, Ceppi L, Sales G, Donati F, Perego P, Zanotti L, Ballabio S, Grassi T, Delle Marchette M, Tognon G, Sartori E, Adorni M, Odicino F, D'Incalci M, Bignotti E, Romualdi C, Marchini S. Benvenuto G, et al. Among authors: ballabio s. Int J Cancer. 2020 Jul 15;147(2):565-574. doi: 10.1002/ijc.32935. Epub 2020 Mar 13. Int J Cancer. 2020. PMID: 32096871
Correction: Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.
Bello E, Brich S, Craparotta I, Mannarino L, Ballabio S, Gatta R, Marchini S, Carrassa L, Matteo C, Sanfilippo R, Gronchi A, Casali PG, Pilotti S, D'Incalci M, Frapolli R. Bello E, et al. Among authors: ballabio s. Br J Cancer. 2020 Mar;122(7):1120. doi: 10.1038/s41416-020-0746-5. Br J Cancer. 2020. PMID: 32047297 Free PMC article.
Combination of PPARγ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas.
Frapolli R, Bello E, Ponzo M, Craparotta I, Mannarino L, Ballabio S, Marchini S, Carrassa L, Ubezio P, Porcu L, Brich S, Sanfilippo R, Casali PG, Gronchi A, Pilotti S, D'Incalci M. Frapolli R, et al. Among authors: ballabio s. Clin Cancer Res. 2019 Dec 15;25(24):7565-7575. doi: 10.1158/1078-0432.CCR-19-0976. Epub 2019 Sep 3. Clin Cancer Res. 2019. PMID: 31481505 Free article.
Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin.
Bello E, Brich S, Craparotta I, Mannarino L, Ballabio S, Gatta R, Marchini S, Carrassa L, Matteo C, Sanfilippo R, Gronchi A, Casali PG, Pilotti S, D'Incalci M, Frapolli R. Bello E, et al. Among authors: ballabio s. Br J Cancer. 2019 Sep;121(6):464-473. doi: 10.1038/s41416-019-0550-2. Epub 2019 Aug 14. Br J Cancer. 2019. PMID: 31409911 Free PMC article.
Multisite analysis of high-grade serous epithelial ovarian cancers identifies genomic regions of focal and recurrent copy number alteration in 3q26.2 and 8q24.3.
Ballabio S, Craparotta I, Paracchini L, Mannarino L, Corso S, Pezzotta MG, Vescio M, Fruscio R, Romualdi C, Dainese E, Ceppi L, Calura E, Pileggi S, Siravegna G, Pattini L, Martini P, Delle Marchette M, Mangioni C, Ardizzoia A, Pellegrino A, Landoni F, D'Incalci M, Beltrame L, Marchini S. Ballabio S, et al. Int J Cancer. 2019 Nov 15;145(10):2670-2681. doi: 10.1002/ijc.32288. Epub 2019 Apr 26. Int J Cancer. 2019. PMID: 30892690
11 results